The evidence to support the cost-effectiveness of allergen immunotherapy (AIT) is limited and of low methodological quality, but suggests that AIT may be cost-effective for people with allergic rhinitis with or without asthma and in high-risk subgroups for venom allergy. Notwithstanding, several gaps such as the comparison of the full range of treatment options (i.e standard care, SCIT, and SLIT) were stated. Aligned with the research priorities of the EAACI the Health economics of allergen immunotherapy task force aims to provide up-to-date evidence of a glowing topic and identify areas to improve all the health-related issues of allergy including the cost-effectiveness of the AIT which modifies the natural course of allergy disorders. Optimization of health care resources is imperative given the costs increase. Moreover, cost-effectiveness studies are currently necessary to pursue excellence and as performance indicators, including the identification of research gaps in this matter.

IG Allergen Immunotherapy

Chair: Darío Antolín-Amérigo

Secretary: Cristina Quecchia